Page last updated: 2024-11-04

2-amino-3-phosphonopropionic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Amino-3-phosphonopropionic acid (APPA) is a non-proteinogenic amino acid that has garnered significant attention in various research fields. APPA is an analog of L-serine, where the hydroxyl group at the 3-position is replaced by a phosphonate group. The compound is a known inhibitor of serine hydroxymethyltransferase (SHMT), an enzyme critical in the synthesis of tetrahydrofolic acid and the metabolism of one-carbon units. APPA's inhibitory properties make it a potential tool for studying SHMT-related processes and diseases. Notably, APPA has demonstrated therapeutic potential in mitigating neurological disorders, particularly in Alzheimer's disease. Its mechanism of action involves inhibiting the formation of amyloid-beta plaques, a key pathological feature of Alzheimer's disease. APPA's ability to modulate the formation of these plaques makes it a promising therapeutic agent for treating Alzheimer's disease. Furthermore, APPA has exhibited antimicrobial activity against bacteria, suggesting its potential in the development of novel antimicrobial therapies. The synthesis of APPA typically involves the reaction of diethyl phosphite with a protected amino acid, followed by deprotection to yield the desired product. Studies on APPA focus on its biological activity, particularly its inhibitory properties against SHMT and its therapeutic applications in treating various diseases, including Alzheimer's disease. '

2-amino-3-phosphonopropionic acid: metabotropic glutamate receptor antagonist; do not confuse AP-3 used as an abbreviation for this with enhancer-binding protein AP-3 (a trans-activator) or clathrin assembly protein AP-3 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-amino-3-phosphonopropanoic acid : A non-proteinogenc alpha-amino acid that is alanine in which one of the hydrogens of the terminal methyl group has been replaced by a dihydroxy(oxido)-lambda(5)-phosphanyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3857
CHEMBL ID88621
CHEBI ID28388
SCHEMBL ID195643
MeSH IDM0040268

Synonyms (85)

Synonym
CHEMBL88621
nsc133887 ,
nsc30078
5652-28-8
nsc-30078
alanine, 3-phosphono-
EU-0100067
dl-2-amino-3-phosphonopropionic acid
3-phosphonoalanine
LOPAC0_000067
C05672
phosphonoalanine
1-AMINO-PROPAN-2-ONE-3-PHOSPHATE ,
2-amino-3-phosphonopropanoate
d-alanyl-phosphate
NCGC00024477-04
NCI60_000747
(?)-2-amino-3-phosphonopropionic acid
2-amino-3-phosphonopropionic acid
NCGC00024477-02
NCGC00024477-03
NCGC00015063-03
( inverted question mark)-2-amino-3-phosphonopropionic acid
2B25DA57-4877-4D7E-B7F2-02DA27BA5498
( inverted question mark)-ap-3
A 4910
NCGC00015063-06
2-amino-3-phosphonopropionate
2-amino-3-phosphonopropanoic acid
20263-06-3
HMS3260M15
3-phosphono-dl-alanine
BMSE000932
ap-3
CCG-204162
3-phosphono-d,l-2-aminopropionic acid, 7
nsc_3857
cas_23052-80-4
bdbm85077
2-amino-3-phosphopropionic acid
nsc 30078
2-amino-3-phosphono-propionic acid
unii-0h89g8110o
2-amino-3-phosprop
0h89g8110o ,
NCGC00015063-04
NCGC00015063-05
FT-0637964
(+/-)-2-amino-3-phosphonopropionic acid
LP00067
AKOS015892997
SCHEMBL195643
NCGC00260752-01
tox21_500067
(y)-2-amino-3-phosphonopropionic acid
dl-2-amino-3-phosphonopropionicacid
dl-alanine, 3-phosphono-
dl-ap3
LBTABPSJONFLPO-UHFFFAOYSA-N
dl-2-amino-3-phosphonopropanoic acid
mfcd00014350
(+/-)-2-amino-3-phosphonopropanoic acid
phosphonic acid, (2-amino-2-carboxyethyl)-
2-ap3
d,l-2-amino-3-phosphonopropionic acid
d,l-2-amino-3-phosphonopropionic acid (h-dl-ala(po3h2)-oh)
sr-01000075416
SR-01000075416-1
STL556264
DTXSID40863590
EX-A7667
(+-)-2-amino-3-phosphonopropionic acid ( ap-3)nmda antagonist
SDCCGSBI-0050055.P003
NCGC00015063-09
nsc 30078; phosphonic acid, (2-amino-2-carboxyethyl)-; alpha-amino-beta-phosphonopropionic acid
D-275
2-amino-3-phosphonopropanoic acid.
CHEBI:28388
2-azanyl-3-phosphono-propanoic acid
2-amino-3-phosphono-propanoic acid
Q27236782
nsc 30078; phosphonic acid, (2-amino-2-carboxyethyl)-; -amino--phosphonopropionic acid
CS-0020425
2-amino-3-phosphonopropanoicacid
HY-100786

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The test compound used was the metabotropic glutamate receptor antagonist, L(+)-2-amino-3-phosphonopropionic acid (L-AP3), which is known to be toxic in vivo after subchronic, but not acute, administration."( Long-term, repeated dose in vitro neurotoxicity of the glutamate receptor antagonist L-AP3, demonstrated in rat hippocampal slice cultures by using continuous propidium iodide incubation.
Blaabjerg, M; Kristensen, BW; Noraberg, J; Zimmer, J, 2007
)
0.57

Dosage Studied

ExcerptRelevanceReference
" These mGluRs are functionally active on catecholamine (CA) secretion in chromaffin cells because both (1S, 3R)-1-aminocyclopentane-1,3-dicarboxylic acid (t-ACPD) and the specific agonist of Group I mGluRs, (S)-3,5-dihydroxyphenylglycine (DHPG), were able to stimulate the release of CAs (adrenaline and noradrenaline) in a dose-response manner."( Expression and functional properties of group I metabotropic glutamate receptors in bovine chromaffin cells.
Aránguez, I; Arce, C; Del Campo, AB; Figueroa, S; González, MP; López, E; Oset-Gasque, MJ, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metabotropic glutamate receptor antagonistAn antagonist at the metabotropic glutamate receptor.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
alanine derivativeAn amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of alanine by a heteroatom. The definition normally excludes peptides containing alanine residues.
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
phosphonic acidsHP(=O)(OH)2 (phosphonic acid) and its P-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Vitamin B6228

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency15.84890.003245.467312,589.2998AID1705
phosphopantetheinyl transferaseBacillus subtilisPotency35.48130.141337.9142100.0000AID1490
arylsulfatase AHomo sapiens (human)Potency37.93301.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency16.37330.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.56230.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
flap endonuclease 1Homo sapiens (human)Potency8.43680.133725.412989.1251AID588795
lamin isoform A-delta10Homo sapiens (human)Potency0.00630.891312.067628.1838AID1487
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency2.81841.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
proteolysisN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
protein deglycosylationN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
N4-(beta-N-acetylglucosaminyl)-L-asparaginase activityN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
protein bindingN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
peptidase activityN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
extracellular spaceN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
lysosomeN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
endoplasmic reticulumN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
azurophil granule lumenN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
cytoplasmN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
lysosomeN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID479489Antimalarial activity against multidrug-resistant Plasmodium falciparum isolate 208432 infected in human erythrocytes after 48 hrs by flow-cytometry2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90.
AID479487Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 48 hrs by flow-cytometry2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90.
AID479485Displacement of bis-ANS from Plasmodium falciparum 3D7 Hsp90 expressed in Escherichia coli BL21(DE3) assessed as reduction in fluorescence at 100 uM after 30 min by fluorescent monochromator spectrophotometry2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90.
AID479488Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human erythrocytes after 48 hrs by flow-cytometry2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90.
AID479486Displacement of bis-ANS from human Hsp90 assessed as reduction in fluorescence at 100 uM after 30 mins by fluorescent monochromator spectrophotometry2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90.
AID74396Concentration required to inhibit glucosamine-6-phosphate synthase (GFAT) isolated from Candida albicans2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Multisubstrate analogue inhibitors of glucosamine-6-phosphate synthase from Candida albicans.
AID74397Inhibitory activity against glucosamine-6-phosphate synthase (GFAT) isolated from Saccharomyces cerevisiae at concentrations <10 mM; NI means no inhibition2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Multisubstrate analogue inhibitors of glucosamine-6-phosphate synthase from Candida albicans.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1799666Inhibition Assay from Article 10.1080/14756360109162375: \\Glycosylasparaginase inhibition studies: competitive inhibitors, transition state mimics, noncompetitive inhibitors.\\2001Journal of enzyme inhibition, , Volume: 16, Issue:3
Glycosylasparaginase inhibition studies: competitive inhibitors, transition state mimics, noncompetitive inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (144)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (5.56)18.7374
1990's99 (68.75)18.2507
2000's17 (11.81)29.6817
2010's13 (9.03)24.3611
2020's7 (4.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.19 (24.57)
Research Supply Index4.99 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other146 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]